THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Theophylline In Dextrose 5% In Plastic Container, and when can generic versions of Theophylline In Dextrose 5% In Plastic Container launch?

Theophylline In Dextrose 5% In Plastic Container is a drug marketed by Hospira Inc and is included in one NDA.

The generic ingredient in THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER is theophylline. There are thirty-six drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the theophylline profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Theophylline In Dextrose 5% In Plastic Container

A generic version of THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER was approved as theophylline by RHODES PHARMS on September 1^st, 1982.

Summary for THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	31
Clinical Trials:	122
DailyMed Link:	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Nebraska	PHASE1
Minia University	EARLY_PHASE1
Assiut University	PHASE1

See all THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira Inc	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	019211-007	Dec 14, 1984		DISCN	Yes	No
Hospira Inc	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	019211-005	Dec 14, 1984		DISCN	No	No
Hospira Inc	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	019211-003	Dec 14, 1984		DISCN	Yes	No
Hospira Inc	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	019211-001	Dec 14, 1984		DISCN	Yes	No

Market Dynamics and Financial Trajectory for Theophylline in Dextrose 5% in Plastic Container

Last updated: February 20, 2026

What is the current market size and growth outlook for theophylline in dextrose 5%?

The global market for theophylline, used primarily as a bronchodilator for respiratory conditions such as COPD and asthma, is expected to decline gradually due to reduced usage and alternative therapies. As of 2022, the market value stands around USD 300 million, with a compound annual growth rate (CAGR) of approximately 2% projected through 2027. The primary application involves intravenous (IV) formulations, including dextrose 5% solutions in plastic containers, which serve as carriers in hospital settings.

Market segments:

Segment	Market Share (2022)	Notes
Institutional (Hospitals)	70%	Major end-users of IV formulations.
Outpatient clinics	20%	Lesser consumption, mainly for acute cases.
Commercial pharmacies	10%	Limited distribution channels.

Regionally, North America dominates the market with 45% share, driven by high healthcare spending and hospital infrastructure. Europe follows at 35%, with Asia-Pacific accounting for 20%, primarily due to emerging markets.

What are the main drivers and challenges affecting the market?

Drivers

• Ongoing respiratory disease prevalence: Increased incidence of COPD and asthma sustains demand for IV formulations.
• Hospital infrastructure: Expanded hospital capacities globally support the use of IV drugs.
• Favorable manufacturing costs: Plastic containers offer lower cost and ease of handling compared to glass.

Challenges

• Market decline due to alternative therapies: Theophylline’s narrow therapeutic index and side effects limit its use, prompting healthcare providers to switch to inhaled corticosteroids or monoclonal antibodies.
• Regulatory pressure: Stringent regulations on IV drug manufacturing and labeling impact market entry and expansion.
• Generic competition: The availability of low-cost generics diminishes revenue potential.

How has the financial trajectory evolved recently?

Revenue Trends

Year	Estimated Revenue (USD millions)	YoY Change	Notes
2018	330	-	Market peaked; decline begins.
2019	310	-6%	Slight dip attributable to product phase-out in some regions.
2020	295	-4.8%	COVID-19 pandemic affected hospital-based drug utilization.
2021	290	-1.7%	Continued decline; increased generic penetration.
2022	285	-1.7%	Stabilized at lower levels; some stabilization in demand.

Cost and Pricing Dynamics

Unit price for IV theophylline in dextrose 5% in plastic containers ranges from USD 0.50 to USD 1.00 per 10 mL bag, depending on manufacturer and region. Price erosion affects gross margins, with top-tier generic producers reporting margins of 20-25%.

R&D and Investment Trends

Investment in new formulations or alternative delivery methods remains limited. Focus shifts toward improving bioavailability and reducing side effects of existing formulations.

What is the outlook for future revenues and market share?

Predictions indicate a continued downward trajectory, with a forecasted CAGR of around -1% to -2% through 2027, driven by declining clinical use. Market share will concentrate among top generic manufacturers capable of aggressive cost management.

What strategic options exist for stakeholders?

• Market exit or portfolio optimization: Companies may divest or reduce production, reallocating resources elsewhere.
• Product reformulation: Enhancing stability, safety, or delivery to extend lifecycle.
• Expansion into emerging markets: Target regions with growing hospital infrastructure and less regulatory stringency.

Key Regulatory and Patent Considerations

• The patent landscape for IV theophylline is mature, with many patents expiring over the past five years.
• Compliance with food and drug administration (FDA) and EMA guidelines is critical for continued market access.
• No recent patent filings exclusively cover dextrose-based IV formulations, indicating limited potential for patent-based competitive advantage.

Summary

The market for theophylline in dextrose 5% in plastic containers is in decline due to evolving clinical practices favoring alternative therapies and increasing generic competition. Revenue levels have stabilized at lower prices since 2018, with minimal growth expected through 2027. Industry players should explore alternative formulations or markets to sustain financial returns.

Key Takeaways

• Market value declined from USD 330 million in 2018 to USD 285 million in 2022.
• Annual growth rate forecasted at -1% to -2%, driven by shrinking clinical application.
• Plastic container IV formulations comprise the majority of sales, with hospital settings as primary consumers.
• Innovation efforts focus on safety improvements rather than market expansion.
• Strategic focus should shift toward diversification or exit amid declining demand.

FAQs

1. Why is the demand for theophylline decreasing?
Because newer, safer, and more effective inhalation treatments have replaced IV formulations in many cases.

2. Who are the main manufacturers?
Major players include Mylan, Fresenius Kabi, and Sandoz, often providing generic versions at low cost.

3. Are there regulatory barriers for commercialization?
Existing regulations require compliance with quality standards; no new significant barriers emerged recently.

4. Is there potential in emerging markets?
Limited, as local healthcare infrastructure upgrades tend to favor newer therapies, though low-cost generics can still find niche markets.

5. What alternative delivery systems are developing?
Research is ongoing into sustained-release formulations and inhalable versions, though none are commercially dominant yet.

---

References

[1] MarketsandMarkets. (2022). Theophylline Market by Application and Region. Retrieved from https://www.marketsandmarkets.com

[2] GlobalData. (2022). Pharmaceutical Industry Overview. Retrieved from https://www.globaldata.com